What are the most common visual symptoms of achromatopsia caused by CNGA3 mutations?

Individuals often report seeing the world in shades of gray, with a complete or near‑complete loss of color vision. They may also experience extreme sensitivity to bright light (photophobia), reduced visual acuity, and difficulty distinguishing objects in bright daylight. These symptoms typically appear in early childhood and persist throughout life.

What tests are used to confirm a CNGA3 mutation, and what does a negative result imply?

Diagnosis involves a comprehensive eye exam (visual acuity, color vision tests, electroretinography) followed by genetic testing that sequences the CNGA3 gene. A negative result does not rule out achromatopsia, as other genes (e.g., CNGB3) can cause similar symptoms; further genetic panels or whole‑exome sequencing may be necessary to identify the underlying cause.

Is there a cure for achromatopsia, and are there any emerging treatments?

Currently, there is no cure, but management focuses on symptom relief: prescription tinted lenses or sunglasses to reduce photophobia, low‑vision aids, and regular ophthalmologic care. Gene‑replacement therapy is under clinical investigation; early trials using viral vectors to deliver a functional CNGA3 gene to cone cells have shown promise in restoring partial color vision and improving visual acuity.

How can I adapt my daily life to cope with achromatopsia?

Practical strategies include using high‑contrast color schemes for clothing and household items, employing bright, even lighting to reduce glare, and using assistive devices such as magnifiers or screen readers. In schools or workplaces, requesting accommodations like larger print, audio descriptions, or color‑blind friendly materials can help maintain independence.

CNGA3 Gene

The CNGA3 gene encodes a subunit of the cyclic nucleotide‑gated channel in cone photoreceptors; mutations in this gene are a common cause of achromatopsia and related cone disorders.

Normal Function

The CNGA3 gene provides instructions for making one part (the alpha subunit) of the cyclic nucleotide‑gated (CNG) channel. These channels are found exclusively in light‑sensing (photoreceptor) cells called cones, which are located in a specialized tissue at the back of the eye. Cones provide color vision and vision in bright light (daytime vision). Other photoreceptor cells, called rods, provide vision in low light (night vision).

CNG channels are openings in the cell membrane that transport positively charged atoms (ions) into cells. The CNG channels in cones remain open in low light, allowing ions to flow in. When light enters the eye, these channels close, stopping the flow of ions. This change in ion transport alters the cone's electrical charge, which ultimately generates a signal. This signal is sent to the brain, where it combines with other visual information and is interpreted as vision. The process of translating light into an electrical signal is called phototransduction.

Health Conditions Related to Genetic Changes

Achromatopsia

Variants (also called mutations) in the CNGA3 gene can cause achromatopsia. Achromatopsia is a disorder of the retina. Some people with achromatopsia cannot perceive any color; they see only black, white, and shades of gray. Other affected individuals can see some color. Approximately 30 to 40 percent of people with achromatopsia have a variant in the CNGA3 gene. CNGA3 gene variants are more common in affected individuals from the Middle East and China.

Most of the CNGA3 gene variants that cause achromatopsia result in the substitution of one protein building block (amino acid) for another in the alpha subunit. This altered protein impairs the function of the CNG channels, which impairs the cones' ability to respond to light. This causes the lack of color vision and contributes to the other vision problems found in people with this condition.

Cone‑rod dystrophy

MedlinePlus Genetics provides information about Cone‑rod dystrophy.

Other disorders

Variants in the CNGA3 gene have also been found in some people with progressive cone dystrophy. Like achromatopsia, this condition affects the function of cones. However, individuals with progressive cone dystrophy begin having problems with cone function in childhood or adolescence. Progressive cone dystrophy causes vision problems, such as an increased sensitivity to light and a reduced ability to see color, that worsen over time. It is unclear why some CNGA3 gene variants cause achromatopsia, while others result in progressive cone dystrophy.

Other Names for This Gene

ACHM2
cyclic nucleotide‑gated channel, alpha‑3

Additional Information & Resources

Tests Listed in the Genetic Testing Registry

Tests of CNGA3

Scientific Articles on PubMed

PubMed

Catalog of Genes and Diseases from OMIM

CYCLIC NUCLEOTIDE‑GATED CHANNEL, ALPHA‑3; CNGA3

Gene and Variant Databases

NCBI Gene
ClinVar

References

Gill JS, Georgiou M, Kalitzeos A, Moore AT, Michaelides M. Progressive cone and cone‑rod dystrophies: clinical features, molecular genetics and prospects for therapy. Br J Ophthalmol. 2019 Jan 24;103(5):711-20. doi:10.1136/bjophthalmol-2018-313278. Online ahead of print. Citation on PubMed
Hirji N, Aboshiha J, Georgiou M, Bainbridge J, Michaelides M. Achromatopsia: clinical features, molecular genetics, animal models and therapeutic options. Ophthalmic Genet. 2018 Apr;39(2):149-157. doi: 10.1080/13816810.2017.1418389. Epub 2018 Jan 5. Citation on PubMed
Johnson S, Michaelides M, Aligianis IA, Ainsworth JR, Mollon JD, Maher ER, Moore AT, Hunt DM. Achromatopsia caused by novel mutations in both CNGA3 and CNGB3. J Med Genet. 2004 Feb;41(2):e20. doi: 10.1136/jmg.2003.011437. No abstract available. Citation on PubMed or Free article on PubMed Central
Koeppen K, Reuter P, Ladewig T, Kohl S, Baumann B, Jacobson SG, Plomp AS, Hamel CP, Janecke AR, Wissinger B. Dissecting the pathogenic mechanisms of mutations in the pore region of the human cone photoreceptor cyclic nucleotide‑gated channel. Hum Mutat. 2010 Jul;31(7):830-9. doi:10.1002/humu.21283. Citation on PubMed
Kohl S, Jagle H, Wissinger B, Zobor D. Achromatopsia. 2004 Jun 24 [updated 2018 Sep 20]. In: Adam MP, Bick S, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews(R) [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2026. Citation on PubMed
Kohl S, Marx T, Giddings I, Jagle H, Jacobson SG, Apfelstedt‑Sylla E, Zrenner E, Sharpe LT, Wissinger B. Total colourblindness is caused by mutations in the gene encoding the alpha‑subunit of the cone photoreceptor cGMP‑gated cation channel. Nat Genet. 1998 Jul;19(3):257-9. doi: 10.1038/935. Citation on PubMed
Li S, Huang L, Xiao X, Jia X, Guo X, Zhang Q. Identification of CNGA3 mutations in 46 families: common cause of achromatopsia and cone‑rod dystrophies in Chinese patients. JAMA Ophthalmol. 2014 Sep;132(9):1076-83. doi:10.1001/jamaophthalmol.2014.1032. Citation on PubMed
Michalakis S, Gerhardt M, Rudolph G, Priglinger S, Priglinger C. Achromatopsia: Genetics and Gene Therapy. Mol Diagn Ther. 2022 Jan;26(1):51-59. doi: 10.1007/s40291-021-00565-z. Epub 2021 Dec 3. Citation on PubMed
Patel KA, Bartoli KM, Fandino RA, Ngatchou AN, Woch G, Carey J, Tanaka JC. Transmembrane S1 mutations in CNGA3 from achromatopsia 2 patients cause loss of function and impaired cellular trafficking of the cone CNG channel. Invest Ophthalmol Vis Sci. 2005 Jul;46(7):2282-90. doi: 10.1167/iovs.05-0179. Citation on PubMed
Reuter P, Koeppen K, Ladewig T, Kohl S, Baumann B, Wissinger B; Achromatopsia Clinical Study Group. Mutations in CNGA3 impair trafficking or function of cone cyclic nucleotide‑gated channels, resulting in achromatopsia. Hum Mutat. 2008 Oct;29(10):1228-36. doi: 10.1002/humu.20790. Citation on PubMed
Sun W, Zhang Q. Diseases associated with mutations in CNGA3: Genotype‑phenotype correlation and diagnostic guideline. Prog Mol Biol Transl Sci. 2019;161:1-27. doi: 10.1016/bs.pmbts.2018.10.002. Epub 2018 Nov 23. Citation on PubMed
Thiadens AA, Roosing S, Collin RW, van Moll‑Ramirez N, van Lith‑Verhoeven JJ, van Schooneveld MJ, den Hollander AI, van den Born LI, Hoyng CB, Cremers FP, Klaver CC. Comprehensive analysis of the achromatopsia genes CNGA3 and CNGB3 in progressive cone dystrophy. Ophthalmology. 2010 Apr;117(4):825-30.e1. doi:10.1016/j.ophtha.2009.09.008. Epub 2010 Jan 15. Citation on PubMed
Trankner D, Jagle H, Kohl S, Apfelstedt‑Sylla E, Sharpe LT, Kaupp UB, Zrenner E, Seifert R, Wissinger B. Molecular basis of an inherited form of incomplete achromatopsia. J Neurosci. 2004 Jan 7;24(1):138-47. doi:10.1523/JNEUROSCI.3883-03.2004. Citation on PubMed
Wissinger B, Gamer D, Jagle H, Giorda R, Marx T, Mayer S, Tippmann S, Broghammer M, Jurklies B, Rosenberg T, Jacobson SG, Sener EC, Tatlipinar S, Hoyng CB, Castellan C, Bitoun P, Andreasson S, Rudolph G, Kellner U, Lorenz B, Wolff G, Verellen‑Dumoulin C, Schwartz M, Cremers FP, Apfelstedt‑Sylla E, Zrenner E, Salati R, Sharpe LT, Kohl S. CNGA3 mutations in hereditary cone photoreceptor disorders. Am J Hum Genet. 2001 Oct;69(4):722-37. doi: 10.1086/323613. Epub 2001 Aug 30. Citation on PubMed or Free article on PubMed Central

Genomic Location

The CNGA3